- Home
- Publications
- Publication Search
- Publication Details
Title
Frontline Therapy of CLL: Evolving Treatment Paradigm
Authors
Keywords
CLL, Chronic lymphocytic leukemia, Frontline, First-line, Upfront, Treatment
Journal
Current Hematologic Malignancy Reports
Volume 13, Issue 2, Pages 69-77
Publisher
Springer Nature
Online
2018-02-26
DOI
10.1007/s11899-018-0438-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia
- (2017) Pawel Robak et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT-NAÏVE CLL/SLL
- (2017) P. Ghia et al. HEMATOLOGICAL ONCOLOGY
- SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB-3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- (2017) C.S. Tam et al. HEMATOLOGICAL ONCOLOGY
- BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)
- (2017) P. Cramer et al. HEMATOLOGICAL ONCOLOGY
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
- (2017) John F Seymour et al. LANCET ONCOLOGY
- Unexpected Pneumocystis jirovecii pneumonia in patients with untreated chronic lymphocytic leukemia
- (2017) Lucile Sesé et al. LEUKEMIA & LYMPHOMA
- A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia
- (2016) Ian W. Flinn et al. AMERICAN JOURNAL OF HEMATOLOGY
- A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL
- (2016) Ian W. Flinn et al. AMERICAN JOURNAL OF HEMATOLOGY
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- AtypicalPneumocystis jiroveciipneumonia in previously untreated patients with CLL on single-agent ibrutinib
- (2016) Inhye E. Ahn et al. BLOOD
- Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity
- (2016) Philip A. Thompson et al. CANCER
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
- (2016) Barbara Eichhorst et al. LANCET ONCOLOGY
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
- (2016) Susan O'Brien et al. LANCET ONCOLOGY
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial
- (2016) Richard Greil et al. Lancet Haematology
- Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia
- (2015) Anthony R. Mato et al. AMERICAN JOURNAL OF HEMATOLOGY
- Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia
- (2015) J. C. Byrd et al. BLOOD
- Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial
- (2015) Jennifer R. Brown et al. BLOOD
- Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
- (2015) D. Rossi et al. BLOOD
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
- (2015) P. A. Thompson et al. BLOOD
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
- (2015) K. Fischer et al. BLOOD
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
- (2015) Mohammed Z H Farooqui et al. LANCET ONCOLOGY
- Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
- (2015) V Goede et al. LEUKEMIA
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients
- (2014) Robin Foà et al. AMERICAN JOURNAL OF HEMATOLOGY
- Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
- (2014) S. Stilgenbauer et al. BLOOD
- Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study
- (2014) Peter Hillmen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of alemtuzumab–rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes
- (2014) Olga Frankfurt et al. LEUKEMIA & LYMPHOMA
- Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes
- (2014) Ohad Benjamini et al. LEUKEMIA & LYMPHOMA
- Monoclonal B-cell lymphocytosis: right track or red herring?
- (2012) P. Ghia et al. BLOOD
- The B-cell receptor signaling pathway as a therapeutic target in CLL
- (2012) J. A. Woyach et al. BLOOD
- Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
- (2012) Sebastian Böttcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling
- (2012) Marcus Dühren-von Minden et al. NATURE
- The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia
- (2010) Y. Herishanu et al. BLOOD
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
- (2009) M. P. Quiroga et al. BLOOD
- Tyrosine kinases and their substrates in B lymphocytes
- (2009) Tomohiro Kurosaki et al. IMMUNOLOGICAL REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now